Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib Dose Optimization in Indolent B-cell Lymphoma
NCT06343935Phase 4Not yet recruiting
- Sponsor
- Yingli Pharma
- Start
- Apr 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of linperlisib in indolent B-cell lymphoma, sponsored by Yingli Pharma. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
linperlisib
03
Conditions
indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT06343935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343935.